William Blair Has Pessimistic Outlook of Agenus Q4 Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities research analysts at William Blair cut their Q4 2024 earnings estimates for shares of Agenus in a note issued to investors on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($2.85) per share for the quarter, down from their previous forecast of ($2.81). The consensus estimate for Agenus’ current full-year earnings is ($10.26) per share. William Blair also issued estimates for Agenus’ Q1 2025 earnings at ($2.90) EPS, Q2 2025 earnings at ($3.07) EPS, Q3 2025 earnings at ($3.22) EPS, Q4 2025 earnings at ($3.31) EPS, FY2025 earnings at ($12.51) EPS, FY2026 earnings at ($13.03) EPS and FY2027 earnings at ($12.97) EPS.

Other research analysts have also recently issued research reports about the stock. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $8.00 in a report on Friday, July 19th. B. Riley decreased their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Jefferies Financial Group restated a “hold” rating and set a $7.00 target price (up from $3.00) on shares of Agenus in a research note on Friday, July 19th. Finally, HC Wainwright reduced their price target on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Agenus Stock Down 1.8 %

NASDAQ:AGEN opened at $2.72 on Friday. Agenus has a 12-month low of $2.58 and a 12-month high of $19.69. The stock’s fifty day simple moving average is $4.70 and its 200-day simple moving average is $8.70. The firm has a market capitalization of $63.81 million, a P/E ratio of -0.24 and a beta of 1.39.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its stake in Agenus by 295.3% in the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 20,777 shares during the last quarter. EP Wealth Advisors LLC bought a new position in Agenus in the 3rd quarter worth about $55,000. State Street Corp boosted its holdings in Agenus by 2.1% in the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the period. Point72 DIFC Ltd increased its holdings in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 11,542 shares during the period. Finally, HighTower Advisors LLC raised its position in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares in the last quarter. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.